FDA’s work crafting guidance documents and dealing with First Amendment litigation may have helped curb enforcement actions against companies for their Rx drug promotional pieces.
FDA's Rx Promotion Citation Drought Continued In 2015
First Amendment litigation and guidance document work may be factors behind decline.